WuXi PharmaTech Acquires Abgent for Antibody Reagents

China's CRO WuXi PharmaTech has announced its acquisition of research reagents manufacturer Abgent.

China-based CRO WuXi PharmaTech has acquired Abgent, a provider of biological research reagent products and services.

Abgent is among the largest manufacturers of antibody reagents for research use. The company has a catalog of approximately 20,000 antibody products and serves as the original manufacturer of antibodies distributed by large reagent suppliers. Abgent also develops and produces peptides and proteins for research and diagnostic applications. The company’s facilities consist of a 34,000-sq.-ft lab in Suzhou and a 10,000-sq.-ft. lab and office in San Diego.

Dr. Chun Wu, founder and chief executive officer of Abgent, will continue to run the Abgent business unit as vice president of Biological Reagent Products and Services.